Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells
Language English Country United States Media print-electronic
Document type Journal Article
- Keywords
- antibodies, apoferritin, doxorubicin, nanomedicine, targeted drug delivery,
- MeSH
- Apoferritins metabolism MeSH
- Doxorubicin administration & dosage MeSH
- Drug Delivery Systems methods MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms drug therapy MeSH
- Antibodies metabolism MeSH
- Antineoplastic Agents administration & dosage MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Apoferritins MeSH
- Doxorubicin MeSH
- Antibodies MeSH
- Antineoplastic Agents MeSH
Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate-specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate-cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 μM) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.
References provided by Crossref.org
Apoferritin as an ubiquitous nanocarrier with excellent shelf life
